Velum
Organisation
People
12 Sept 2025, reporter.nih.gov
Grants and prizes
National Institute of Diabetes and Digestive and Kidney Diseases
R42, A Robust Platform for Design and Development of Therapeutic Peptides for Metabolic Syndrome, R42DK131842, US$959k, 2022–2027, 12 Sept 2025, reporter.nih.gov
National Institute of Diabetes and Digestive and Kidney Diseases
R41, Peptide YY triagonist weight loss drugs, R41DK145340, US$315.3k, 2025–2027, 26 Aug 2025, reporter.nih.gov
R42, A GIP Companion Drug for Enhancing Metabolic Benefits of Long-Acting GLP-1, R42AG061909, US$478.3k, 2018–2025, 4 May 2023, reporter.nih.gov